INTRODUCTION: Central nervous system demyelination caused by immune checkpoint inhibitors is a very rare condition. CASE PRESENTATION: A 65-year-old man who received nivolumab for renal cell carcinoma developed abnormal behavior, such as disagreeable speech and sudden anger. Brain-enhanced magnetic resonance imaging revealed multiple lesions with partial contrast effects in the cerebral white matter. We tentatively diagnosed demyelination caused by nivolumab, and performed steroid pulse therapy twice. After that, his symptoms improved. For the next 2 years, his symptoms did not recur, nor did his cancer progress. CONCLUSION: Demyelination caused by immune checkpoint inhibitors can be fatal and requires early diagnosis and treatment.
INTRODUCTION: Central nervous system demyelination caused by immune checkpoint inhibitors is a very rare condition. CASE PRESENTATION: A 65-year-old man who received nivolumab for renal cell carcinoma developed abnormal behavior, such as disagreeable speech and sudden anger. Brain-enhanced magnetic resonance imaging revealed multiple lesions with partial contrast effects in the cerebral white matter. We tentatively diagnosed demyelination caused by nivolumab, and performed steroid pulse therapy twice. After that, his symptoms improved. For the next 2 years, his symptoms did not recur, nor did his cancer progress. CONCLUSION: Demyelination caused by immune checkpoint inhibitors can be fatal and requires early diagnosis and treatment.
Authors: S Cuzzubbo; F Javeri; M Tissier; A Roumi; C Barlog; J Doridam; C Lebbe; C Belin; R Ursu; A F Carpentier Journal: Eur J Cancer Date: 2017-01-05 Impact factor: 9.162
Authors: Yonghao Cao; Alyssa Nylander; Sriram Ramanan; Brittany A Goods; Gerald Ponath; Rana Zabad; Veronica L S Chiang; Alexander O Vortmeyer; David A Hafler; David Pitt Journal: Neurology Date: 2016-03-16 Impact factor: 9.910
Authors: Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson Journal: J Clin Oncol Date: 2018-02-14 Impact factor: 44.544
Authors: Sarah Mancone; Thomas Lycan; Tamjeed Ahmed; Umit Topaloglu; Andrew Dothard; William J Petty; Roy E Strowd Journal: J Neurol Date: 2018-05-14 Impact factor: 4.849
Authors: Catherine Maurice; Raphael Schneider; Tim-Rasmus Kiehl; Prashant Bavi; Michael H A Roehrl; Warren P Mason; David Hogg Journal: Cancer Immunol Res Date: 2015-09-29 Impact factor: 11.151
Authors: I Puzanov; A Diab; K Abdallah; C O Bingham; C Brogdon; R Dadu; L Hamad; S Kim; M E Lacouture; N R LeBoeuf; D Lenihan; C Onofrei; V Shannon; R Sharma; A W Silk; D Skondra; M E Suarez-Almazor; Y Wang; K Wiley; H L Kaufman; M S Ernstoff Journal: J Immunother Cancer Date: 2017-11-21 Impact factor: 13.751